Concepedia

Author

Dan Combs

Czech Academy of Sciences, Institute of Analytical Chemistry

Also Known As

D. Combs, Dan Combs

11

Publications

1.6K

Citations

8

H-Index

20

Concepts

All Affiliations

Czech Academy of Sciences, Institute of Analytical Chemistry
DC

About

Dan Combs is an author at Czech Academy of Sciences, Institute of Analytical Chemistry specializing in immunology, immunotherapy, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

113

2

Immunology

2

2

113

3

Health Sciences

1

1

34

4

Cell Biology

1

1

79

5

Cellular Therapies

1

1

34

Dan Combs

×

7

Publications

1.3K

Citations

7

H-Index

YearCitations

Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins

Mark S. Dennis, Min Zhang, Miryam Kadkhodayan,

Journal of Biological Chemistry

2002

494

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

James L. Rubenstein, Dan Combs, J. Rosenberg,

Blood

2002

419

Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial

Chee M. Ng, René Bruno, Dan Combs,

The Journal of Clinical Pharmacology

2005

197

Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis

Yulia Vugmeyster, Joseph C. Beyer, Kathy Howell,

Journal of Immunotherapy

2005

79

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Clinical Study

Hazel Hunt, Kirsteen Donaldson, Mark Strem,

Clinical Pharmacology in Drug Development

2017

60

Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as ‘in vivo purge’ and consolidative immunotherapy following autologous stem cell transplantation

Joy Mangel, Rena Buckstein, Kevin Imrie,

Annals of Oncology

2003

34

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D<sub>2</sub>/D<sub>3</sub> Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants

R.L. Whiting, Börje Darpö, Chunlin Chen,

Clinical Pharmacology in Drug Development

2021

12

Page 1